Inoperable non–small-cell lung cancer has become the domain of combined-modality treatment based on several recent, large, phase III studies. Results of Radiation Therapy Oncology Group (RTOG) phase II studies have
Roger W. Byhardt, MD
Advertisement
Articles by Roger W. Byhardt, MD
Advertisement
Latest Updated Articles
- Toxicities in RTOG Combined-Modality Trials for Inoperable Non–Small-Cell Lung Cancer
Published: October 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
M. Peter Marinkovich, MD, on Integrating Gene Therapy into Clinical Practice for Dermatologists
2
Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE
3
Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy
4
Quarter Century Update: Platform Approaches and Industry Investment
5
